Argent Biopharma (AU:RGT) has released an update.
Argent BioPharma has announced a strategic partnership with SINTEF to tackle the global challenge of chronic wound management using nano-formulations. This collaboration aims to develop novel antimicrobial agents and improve drug delivery to enhance treatment efficacy, particularly in the face of antibiotic-resistant infections. The initiative is part of Argent BioPharma’s expansion into new therapeutic areas, promising to keep stakeholders informed as research progresses.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.
